Safety and pharmacokinetics study of adalimumab with Halozyme's proprietary ENHANZE technology

Trial Profile

Safety and pharmacokinetics study of adalimumab with Halozyme's proprietary ENHANZE technology

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2016

At a glance

  • Drugs Adalimumab (Primary) ; Hyaluronidase
  • Indications Immunological disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 21 Nov 2016 According to a Halozyme Therapeutics, Inc media release, AbbVie has discontinued a development program using the Halozyme ENHANZE™ platform technology and the tumor necrosis factor alpha (TNF-alpha) target following completion of this study in which the target results were not achieved.
    • 21 Nov 2016 Status changed from recruiting to completed, as per a Halozyme Therapeutics media release.
    • 25 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top